RxDoctor Payments Data

Sarah Riley, PA

Medical · Columbus, OHNPI 1952818312

Payments from drug & device makers

$3,814in general payments, 2019–2025

Across 244 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$719
  • Novartis$430
  • Johnson & Johnson$423
  • GSK$280
  • Pfizer$221
  • plus $293 from 7 others

What the payments were for

  • Food & beverage$3,75999%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie94$1,450
Amgen(2 entities)65$719
Novartis18$430
Johnson & Johnson23$423
GSK16$280
Pfizer15$221
Boehringer Ingelheim1$101
UCB, Inc.5$98
Genentech USA, Inc.3$29
Sanofi1$27
E.r. Squibb & Sons, L.L.C.1$15
AstraZeneca1$12
Neurometrix Inc1$11

How this compares

$3,814 in reported general payments places this provider in the 85th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$95,948
Medicare patients
241
Services billed
7,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab19$278,206
EnbrelEtanercept14$147,319
Enbrel SureclickEtanercept15$133,319
SimponiGolimumab16$129,248
Xeljanz XrTofacitinib Citrate13$88,927
XeljanzTofacitinib Citrate13$84,118
Hydroxychloroquine Sulfate151$7,292
MethotrexateMethotrexate Sodium223$5,599
Leflunomide85$4,807
Celecoxib58$2,837
Duloxetine Hcl71$2,679
Gabapentin107$1,915
Prednisone145$987
Lidocaine13$946
Methylprednisolone42$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$719$147,31914 claims
Johnson & JohnsonSimponi$423$129,24816 claims
PfizerXeljanz$221$84,11813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 547 medical providers in Ohio.

Other medical in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →